Delivery Order SPE2DB25D3020-SPE2DB25FWGDE

Award Date 2/26/25
Potential Completion Date 2/27/25
Potential Value $1.4K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of RESTASIS 0.05% eye emulsion. The contract has a ceiling value of $71,009.21 and an ultimate completion date of February 10, 2025. The contract is a firm fixed-price delivery order, with no set-aside designation. Amerisourcebergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of RESTASIS 0.05% eye emulsion, a specialty pharmaceutical product, to support federal healthcare programs. The contract has a ceiling value of $2,678.62 and a period of performance through January 7, 2025. The contract is a firm-fixed-price delivery order, with no set-aside...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of RESTASIS 0.05% eye emulsion. The contract has a ceiling value of $4,527.84 and an ultimate completion date of January 8, 2024. The contract is a firm fixed-price delivery order, with no set-aside designation, indicating open competition. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $2,160.96, is for the delivery of RESTASIS 0.05% eye emulsion, with a completion date of February 15, 2023. The contract is a firm fixed-price, delivery order type, and was not designated with a set-aside requirement, indicating open competition. Amerisourcebergen holds a significant...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of RESTASIS 0.05% eye emulsion, a prescription medication, with a ceiling value of $43,433.74 and a performance period through May 2, 2024. The contract is a firm fixed-price delivery order, with no set-aside designation. AmerisourceBergen holds a significant Indefinite Delivery...
This is a delivery order awarded to Amerisourcebergen Drug Corp by the Defense Logistics Agency (DLA) for the supply of RESTASIS 0.05% eye emulsion. The contract has a ceiling value of $12,425.52 and a performance period ending on July 23, 2024. The contract is a firm fixed-price arrangement and is not set aside for any specific business type. Amerisourcebergen is a major supplier of pharmaceutical products and medical supplies to the U.S. federal government, holding several Indefinite...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Restasis 0.05% eye emulsion. The contract has a ceiling value of $3,088.44 and a period of performance through November 28, 2022. It is a firm-fixed-price contract, with no set-aside designation. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical through November 2026,...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Restasis 0.05% eye emulsion. The contract has a ceiling value of $2,481.01 and runs through December 14, 2023. It is a firm fixed-price contract with no set-aside designation, indicating open competition. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, which serves as a...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp's Corporate Office Division. The contract is for the supply of RESTASIS 0.05% eye emulsion, a specialty pharmaceutical product, with a ceiling value of $4,056.44 and a performance period that ends on August 8, 2024. The contract is a firm fixed-price delivery order, with no set-aside designation. Amerisourcebergen is a major supplier of pharmaceutical products and medical supplies to the U.S....
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp for the supply of RESTASIS 0.05% eye emulsion. The contract has a ceiling value of $1,891.07 and an ultimate completion date of September 20, 2024. This is a firm fixed-price contract with no set-aside designation. AmerisourceBergen, a major pharmaceutical distributor, has been awarded multiple federal contracts and Indefinite Delivery Contracts (IDCs) by various defense and civilian...
  • SPE2DB25D3020
    Indefinite Delivery Contract
  • SPE2DB25D3020-SPE2DB25FWGDE
    Delivery Order

This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to the prime contractor Amerisourcebergen Drug Corp. The contract is for the pharmaceutical product RESTASIS 0.05% Eye Emulsion, with a ceiling value of $1,447.54 and a period of performance through February 27, 2025. The contract is a firm fixed-price delivery order, with no set-aside designation. Amerisourcebergen Drug Corp is a major pharmaceutical distributor and healthcare solutions provider that has established itself as a key vendor for federal healthcare programs, particularly within military and veterans' healthcare systems. The company holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally.

Generated 5/28/25, 11:01 AM